Alvotech Collaborates with Dr. Reddy’s to Commercialize AVT03 (Biosimilar, Prolia & Xgeva)
Shots:
- Alvotech & Dr. Reddy’s have signed a license & supply agreement to commercialize AVT03 under which Alvotech will handle the development & manufacturing activities. Dr. Reddy will get regulatory & commercial rights exclusively in US and semi-exclusively in the EU & UK
- Alvotech will receive an upfront, regulatory & commercial milestones as well as sales-based payments
- Additionally, in Jan 2024, the company reported top-line data of a PK study assessing safety, PK & tolerability of AVT03 vs Prolia in healthy adults. A confirmatory efficacy & safety study in patients & a PK study of AVT03 vs Xgeva in healthy adults are ongoing
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Reports Data from the Trial of AVT03 (Biosimilar, Prolia and Xgeva) for Skeletal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
